Author

Mary Dickinson Chamberlin

Dartmouth CollegeORCID 0000-0002-6821-5206Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:proteomics· 2 Approach:biophysical modeling· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Adrienne A. WorkmaniD· 1 shared Alyssa M. RobertsiD· 1 shared Arminja Nadine KettenbachiD· 1 shared Candice C. BlackiD· 1 shared Christo Philip C. DragneviD· 1 shared Eugene DemidenkoiD· 1 shared F. W. KollingiD· 1 shared George J. ZanazziiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPathology

Adrienne A. WorkmanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

PathologybioRxivPreprintFeb 11, 2026

X-SPATIO: An Explanatory Deep Learning Pipeline for the Prediction and Visualization of Spatially Resolved Biomarker Expression in Triple-Negative Breast Cancer

V. Madhusudhan Rao, Madhumala K. Sadanandappa, Candice C. Black…·Shrey Sukhadia

X-SPATIO predicts and visualizes spatially resolved biomarker expression in TNBC by linking H&E morphology with spatial transcriptomic and proteomic data.

2 citations

humanspatial transcriptomics

𝕏 PostBluesky

Cancer BiologyCancer ResearchPeer-reviewedJan 8, 2025

Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylation

Steven S. Tau, Mary Dickinson Chamberlin, Huijuan Yang…·Todd W. Miller

This study identifies mitochondrial oxidative phosphorylation as a metabolic vulnerability in endocrine-tolerant persister ER+ breast cancer cells, suggesting therapeutic targeting of mitochondrial function could prevent recurrence.

29 citationstop 1%

humanproteomics

𝕏 PostBluesky